BIIB: UK Approves LEQEMBI®—Investors Take Note!

Introduction

Biogen Inc. (NASDAQ: BIIB) and partner Eisai achieved a milestone in August 2024 when the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved Leqembi (lecanemab) for early-stage Alzheimer’s disease (^[1]). This made Great Britain the first country in Europe to authorize the amyloid-targeting antibody, which showed evidence of slowing cognitive decline (^[1]). However, investors should temper enthusiasm with realism: the U.K.’s National Institute for Health and Care Excellence (NICE) deemed Leqembi’s benefit “too small to justify the cost,” declining to recommend it for National Health Service coverage (^[2]). NICE highlighted that lecanemab provides only a 4–6 month slowing in progression on average – not enough, in its view, to warrant the significant expense and bi-weekly infusion burden on the healthcare system (^[2]) (^[3]). This mixed outcome encapsulates the opportunity and challenges facing Biogen. On one hand, Leqembi’s approval abroad signals growing global traction for a drug that Biogen co-commercializes as a potential new revenue engine. On the other, access and adoption hurdles – from restrictive labels (e.g. excluding certain high-risk gene carriers (^[1])) to payer pushback on cost-effectiveness – could limit the near-term financial windfall. Biogen’s stock has already reflected some of these uncertainties: shares swooned roughly 40% in 2024 amid setbacks in its core multiple sclerosis business and cautious Alzheimer’s drug uptake (^[4]). Below, we dive into Biogen’s dividend policy, balance sheet, valuation, and key risks to evaluate how the Leqembi development fits into the broader investment picture for BIIB.

Dividend Policy & Shareholder Returns

Biogen has never paid a cash dividend since its inception, and it currently has no plans to initiate one (^[5]). The company instead opts to return capital via share repurchases when appropriate. Under a $5.0 billion buyback authorization from 2020 (with no set expiration), Biogen repurchased approximately 3.6 million shares for about $750 million in 2022, but paused buybacks in 2023 and 2024 (^[5]). As of year-end 2024, $2.1 billion remained available under this program for future repurchases (^[5]). The absence of a dividend means Biogen’s dividend yield is 0%, so investors seeking income will not find it here. Management has indicated they continually review capital allocation (including the possibility of dividends), but priority has been given to strategic uses of cash such as acquisitions and buybacks (^[5]). Notably, Biogen spent ~$6.5 billion in 2023 to acquire Reata Pharmaceuticals, reflecting a focus on pipeline expansion over immediate shareholder payouts (^[4]). In short, Biogen’s shareholder return policy skews toward buybacks and reinvestment rather than dividends – sensible for a biotechnology company emphasizing R&D and new product launches over cash distribution. Investors in BIIB should primarily expect returns via stock price appreciation (a function of business success) and occasional buyback-driven EPS accretion, rather than any steady income stream.

Leverage, Debt Maturities & Interest Coverage

Biogen’s balance sheet leverage appears moderate, with a debt profile that is long-dated and manageable. As of December 31, 2024 the company had $4.55 billion in long-term debt outstanding (^[5]), consisting of several senior notes maturing between 2030 and 2051. In addition, about $1.75 billion comes due in September 2025 in the form of a 4.05% Senior Note, now classified as the current portion of debt (^[5]). Collectively, total debt is roughly $6.3 billion, offset by a cash and equivalents balance of approximately $2.4 billion at 2024 year-end (^[5]). Biogen made use of debt in 2023 to fund its Reata acquisition – drawing a $1.0 billion term loan – but aggressively paid this down within months. In fact, the remaining $500 million 364-day loan was fully repaid by early 2024, and a $500 million three-year tranche was completely repaid by mid-2024 (^[5]) (^[5]). The company also refinanced its credit facility in 2024 with a new $1.5 billion revolver, which was undrawn as of year-end and provides additional liquidity if needed (^[5]).

Crucially, Biogen’s debt maturities are well staggered, with no significant obligations after the 2025 note until 2030 (^[5]) (^[5]). The outstanding bonds also carry relatively low fixed interest rates (e.g. 2.25% on the 2030 notes, 3.15–5.20% on longer-dated notes) (^[5]), keeping annual interest costs reasonable. In 2024, Biogen’s net interest expense was about $183 million (^[5]), which is very well covered by its earnings and cash flow. By comparison, income before taxes was roughly $1.9 billion in 2024 (^[5]), implying interest coverage on the order of 10× or more. Even on a cash flow basis, the company generates ample EBITDA/operating cash to service debt obligations comfortably. Overall, Biogen’s leverage appears conservative, and management’s swift repayment of short-term debt signals a prudent approach to balance sheet risk. Barring a large new acquisition, the company looks capable of handling the upcoming 2025 maturity (using cash on hand or refinancing) without strain. For investors, this means financial risk from debt is relatively low – Biogen’s capacity to invest in R&D and new products should not be constrained by its debt load or interest burden in the near term.

Valuation & Comparables

After a volatile few years, Biogen’s valuation now appears modest relative to earnings and peers. The stock’s pullback in 2024 – when BIIB lost roughly 40% of its value (^[4]) – has compressed its trading multiples. As of year-end 2024, Biogen traded around $150–$160 per share, which equated to a trailing price-to-earnings (P/E) ratio near 13.7× based on 2024 earnings (^[6]). This P/E is below the broader market average and suggests a degree of investor skepticism is already priced in. Even on a forward-looking basis, Biogen remains inexpensive. The company earned about $16.47 per share on an adjusted basis in 2024 (^[4]), and management guided to a slight EPS decline in 2025 (mid-$15 range) as multiple sclerosis revenues erode. With the stock in the mid-$140s by early 2025, the forward P/E was roughly 9×–10×, a deep discount to the pharma/biotech sector. In fact, by November 2025 Biogen’s P/E had dipped into the single digits (~9.3×) (^[6]) – a level usually reserved for either low-growth stalwarts or companies facing serious uncertainty.

Comparatively, large-cap pharma peers with promising Alzheimer’s programs trade at richer valuations. For example, Eli Lilly – whose competing Alzheimer’s antibody donanemab was approved in the U.S. in 2023 – has often commanded P/E multiples well above 30×, reflecting high growth expectations for its pipeline. Biogen’s lower multiple likely reflects both its maturing legacy franchises and questions about the scale and speed of Leqembi’s success. In other words, the market is taking a “wait and see” approach. If Leqembi and other new launches ramp up to offset declines in Biogen’s older products, one could argue BIIB is undervalued at current levels. The company’s price-to-sales is only about 2.5× (with ~$9.7B revenue in 2024 (^[5]) and a ~$22B market cap), and EV/EBITDA is similarly in the low-teens range – not demanding for a biotech with a potentially groundbreaking Alzheimer’s drug. However, that upside will only be realized if Biogen can navigate the challenges ahead. For now, Biogen offers value-oriented investors a low-multiple stock, but without the safety net of a dividend and with significant execution risk tied to its product pipeline.

Risks & Red Flags

Despite the optimism around Leqembi, Biogen faces meaningful risks and red flags that investors should weigh:

– Limited Leqembi Uptake & Reimbursement Barriers: A key risk is that Leqembi’s real-world uptake may disappoint. The drug’s clinical benefit, while statistically significant, is modest – roughly a few months’ delay in cognitive decline (^[2]) – and it carries serious side-effect risks (brain swelling or bleeding known as ARIA). This has made payers cautious. The NICE decision not to cover Leqembi due to cost-effectiveness concerns is a stark warning (^[2]). Other health systems, in Europe and elsewhere, could impose similar limits unless Biogen/Eisai offer steep discounts or new data show greater benefit. Even in the U.S., where Medicare will cover Leqembi for approved patients, the high list price (~$26,500 per year initially) and infrastructure needs (bi-weekly infusions, periodic MRI scans for ARIA monitoring) could constrain how many patients start and stay on therapy. Investor expectations that Leqembi will be a multi-billion dollar blockbuster might not materialize if these barriers persist.

– Safety and Label Restrictions: Regulators are trimming Leqembi’s target population to enhance safety. Both the UK and EU regulators excluded patients with two copies of the ApoE4 gene (about 15% of Alzheimer’s patients) from Leqembi’s label due to their higher risk of dangerous ARIA side effects (^[1]) (^[7]). This means the treatable pool is smaller than the total Alzheimer’s population. Moreover, any high-profile adverse events (such as patient deaths or severe brain edema) could further dampen physician and patient willingness to use the drug. Biogen has to carefully manage these safety risks – a difficult balancing act when expanding access to a drug that, by its mechanism (amyloid clearance), inherently carries risk of brain inflammation.

– Competition in Alzheimer’s Treatments: Biogen is not alone in the race. Eli Lilly’s donanemab (brand name Kisunla) works via a similar amyloid-clearing approach and was approved by the FDA in 2023, with the UK MHRA following suit in late 2024 (^[8]). Like Leqembi, Lilly’s drug was also deemed too expensive for NHS use initially (^[8]), but the two products will likely compete for eligible patients globally. Lilly’s donanemab has shown comparable efficacy (also slowing disease progression by a few months) and might even clear plaques faster, according to some analyses. If one drug gains a perception of better efficacy or safety, it could dominate the market. Additionally, several next-generation Alzheimer’s therapies are in development (targeting other pathways like tau protein). A more effective treatment in the future could rapidly render Leqembi (and donanemab) second-line. For Biogen, there is a risk that Leqembi’s commercial window of opportunity could be narrower than hoped if competitors overtake it in innovation or execution.

– Declining Legacy Product Revenues: Outside of Alzheimer’s, Biogen faces pressure on its established franchises. The company’s decades-old core business in multiple sclerosis (MS) is eroding due to fierce competition and patent expirations (^[4]) (^[4]). In the most recent quarter, Biogen’s MS drug sales (e.g. Tecfidera, Avonex, Tysabri) fell around 8% year-over-year (^[4]), a trend expected to continue as generics and new competitors (like Roche’s Ocrevus and Novartis’ Kesimpta) win market share. Spinal muscular atrophy drug Spinraza is another important product that has seen slowing growth due to a one-time gene therapy (Novartis’ Zolgensma) and a rival oral therapy from Roche. These headwinds mean Biogen’s overall revenue has been flat-to-declining (2024 revenue ~$9.68B, down from $10.17B in 2022 (^[5])). The risk is that new product sales may not ramp up fast enough to offset the slide in legacy drugs, creating a growth gap. Indeed, Biogen projects a mid-single-digit revenue decline in 2025 as MS sales shrink (^[4]), even accounting for Leqembi’s growth.

– Pipeline and R&D Setbacks: Biogen has had its share of pipeline disappointments. A recent example is the partnership with Sage Therapeutics: the firms developed zuranolone (Zurzuvae) for depression, but the FDA in 2023 approved it only for postpartum depression, not the much larger major depressive disorder indication, drastically limiting its market (^[9]). This was a setback that contributed to Biogen’s stock weakness and led management to reassess their R&D strategy. Biogen also paid a high price for Reata in 2023 to obtain Skyclarys (for a rare neuromuscular disease), and it remains to be seen if that investment pays off. More broadly, drug development in neurological diseases is high-risk, and Biogen’s pipeline (which includes investigational therapies for Alzheimer’s, ALS, Parkinson’s, lupus, etc.) could yield more failures or regulatory hurdles. Any major trial failure or safety scare can quickly become a red flag, not only wasting R&D dollars but also undermining the company’s growth narrative. Biogen’s history with Aduhelm – the controversially approved Alzheimer’s drug in 2021 that flopped commercially amid insurer backlash – looms as a reminder of how things can go wrong even post-approval. Investors should keep an eye on upcoming clinical readouts and regulatory decisions as potential risk inflection points.

– Regulatory and Policy Risks: The pharmaceutical sector faces external risks such as drug pricing reforms and regulatory scrutiny. While Biogen’s new Alzheimer’s therapy commands a high price, authorities may push for price negotiations or impose usage criteria (e.g., requiring biomarker confirmation and enrollment in registries, as Medicare initially did). Additionally, the Inflation Reduction Act in the U.S. enables Medicare to negotiate prices on certain older drugs; if any of Biogen’s mature drugs qualify in coming years, it could dent those revenues. The company also now incurs a 1% excise tax on stock buybacks (per the 2022 IRA law) (^[5]), which slightly increases the cost of returning cash to shareholders. These factors, while not unique to Biogen, add background risk to the investment picture.

In sum, Biogen faces a challenging balancing act: executing a successful launch of Leqembi and other new therapies to reinvigorate growth, while managing the decline of older franchises and navigating safety, competition, and payer obstacles. The stock’s depressed valuation reflects many of these risks, but it also means the bar for positive surprise is low – execution will be key.

Open Questions & Outlook

Looking ahead, several open questions will determine Biogen’s trajectory and whether the stock’s current discount is justified or an opportunity:

– Can Leqembi Achieve Broader Adoption? Biogen expects a “linear trend” of growth for Leqembi in the near term rather than explosive uptake (^[10]). U.S. sales were only ~$39 million in Q3 2024 (^[10]), indicating gradual uptick. A critical question is whether uptake can accelerate. Recent developments may help. Notably, in late 2025 the FDA approved a subcutaneous injectable form of Leqembi as maintenance therapy, priced at a lower annual cost (~$19,500) and more convenient than IV infusions (^[11]). This could improve patient access and adherence, addressing some cost and logistical concerns that hindered uptake (^[11]). If the subcutaneous option is widely adopted, we might see more patients staying on Leqembi longer, expanding its revenue potential. Investors will be watching prescription and infusion center capacity, the rollout of this injector, and any signs of inflection in the sales trajectory through 2025–2026.

– Will Health Authorities Soften Their Stance? The U.K. and some European bodies have cast doubt on paying for Leqembi at its current cost-effectiveness profile. An open question is whether outcomes data or pricing negotiations can change that. NICE’s verdict is in draft consultation (^[3]) – could Biogen and Eisai offer a discount or additional data to gain at least limited NHS coverage? Likewise in the EU, the European Medicines Agency initially rejected Leqembi, then reversed to recommend approval for a narrower patient group (^[1]) (^[7]). The European Commission formally authorized lecanemab in spring 2025 for early Alzheimer’s patients with 0 or 1 ApoE4 gene (excluding high-risk patients) (^[7]). However, actual uptake in Europe will depend on each country’s willingness to reimburse. Europe could account for “up to 30% of worldwide peak sales” of Leqembi if fully reimbursed (^[7]), but that upside may go unrealized if payers follow NICE’s hard line on value. This leaves a crucial question: will Biogen sacrifice pricing to broaden access in national health systems, or accept smaller markets at a premium price? The answer will directly impact Leqembi’s ultimate revenue scale.

– How Will Competition and Combo Therapies Evolve? Another uncertainty is the competitive landscape in Alzheimer’s treatment. Biogen currently has a first-mover advantage in Europe (since Lilly’s donanemab was rejected by EMA in 2025 over safety/benefit concerns (^[12])), but in the U.S. both drugs compete head-to-head. It’s an open question how physicians will choose between Leqembi vs. donanemab – will one demonstrate a clearer advantage or better safety in real-world practice? Additionally, could combining anti-amyloid drugs with future anti-tau therapies yield better results? Biogen is working on BIIB080 (an experimental drug targeting tau protein) and other compounds (^[9]). If a synergistic approach emerges (for example, using Leqembi to clear amyloid and another agent to address tau tangles), it might extend the relevance of these drugs. Conversely, if a next-gen therapy (like an oral pill or vaccine) comes along that is safer and more effective, it could abruptly curtail the opportunity for monoclonal antibodies. Investors are essentially betting that Biogen’s bet on amyloid pays off before something better arrives. Any breakthroughs at competitors or in Biogen’s own labs (positive or negative) will heavily influence BIIB’s outlook.

– Can Biogen’s Pipeline Fill the Gap? CEO Christopher Viehbacher has set expectations that new product launches will surpass Biogen’s current revenues by 2028 (^[9]). Achieving that would mean not only growing Leqembi, but also success from other pipeline candidates – in areas like depression (SAGE-217/Zurzuvae for MDD, if redevelopment is pursued), lupus (the telitacicept acquisition), ALS (tofersen, already approved for a genetic ALS subset), and neuromuscular diseases (Reata’s Skyclarys for Friedreich’s ataxia). An open question is how much these can contribute and how fast. Some, like Skyclarys, address very small populations, limiting sales potential. Others are in early trials and inherently risky. Biogen’s strategy under the new CEO seems to be focused and disciplined (with a $1B cost-cutting program to redirect resources to R&D (^[4])), but will it bear fruit? If pipelines assets falter or take longer than expected, Biogen might struggle to hit that 2028 goal, and management could feel pressure to pursue additional acquisitions (despite saying there’s “no burning need” for more deals now (^[9])). The company’s R&D productivity in the next 2–3 years will be pivotal. Investors should watch upcoming trial data (e.g. the Phase 3 for anti-tau, Phase 2 for lupus drug, etc.) closely – positive results could fill in the growth story, while disappointments would raise “what now?” questions for Biogen’s long-term strategy.

– Macroeconomic and Financial Flexibility: Lastly, it’s worth questioning how external factors might impact Biogen. Rising interest rates or economic downturns typically affect biotech funding and valuations. Biogen’s strong balance sheet and cash flow afford it some insulation – it doesn’t need to raise capital or debt urgently, and it has liquidity to weather storms. But if, for example, credit markets tightened severely by 2025 when the ~$1.75B debt comes due, refinancing might become more costly (though Biogen could simply use cash on hand to pay it off (^[5])). Similarly, currency fluctuations can impact results (as noted with a stronger dollar hurting 2025 profits (^[4])), since Biogen sells internationally. These are more minor concerns, yet still open-ended as the global economy shifts. The main financial flexibility question for Biogen is: will it continue prioritizing share buybacks (now that the stock is cheap) or conserve cash for pipeline investment? In 2023–2024, Biogen refrained from buybacks and chose acquisitions/R&D (^[5]). If the outlook improves, the company might resume repurchases from its remaining $2.1B authorization, which could provide a tailwind to EPS. Investors will be watching capital allocation signals as a gauge of management’s confidence in internal opportunities versus the attractiveness of its own stock.

In conclusion, Biogen offers a classic risk-reward scenario. The company is at a crossroads: it has a foothold in the potentially transformative Alzheimer’s therapy market, but obstacles to monetizing that opportunity abound. Meanwhile, its legacy business is shrinking, putting pressure on new drugs to carry the torch. The UK’s approval of Leqembi was a significant achievement – one that investors should indeed take note of, as it validates Biogen’s long quest in Alzheimer’s and opens a new market. Yet, the guarded stance of NICE reminds us that sales won’t simply materialize without proving value to payers and physicians. For BIIB shareholders, the coming years will be a test of execution. If Biogen can expand Leqembi’s adoption (helped by measures like a more convenient injection formulation) (^[11]), capitalize on its pipeline, and stabilize its core franchises, the current low valuation leaves ample room for upside. If not, the stock could languish or fall further. Investors should keep a close watch on regulatory decisions, sales trends, and R&D milestones – these will drive whether Biogen’s bold bets translate into shareholder rewards or more challenging questions ahead. The UK green light for Leqembi is one bright step forward, but it’s just the beginning of a long journey for Biogen and its investors.

Sources

1. https://fiercepharma.com/pharma/eisai-biogens-leqembi-nabs-uk-nod-reimbursement-remains-elusive
2. https://biospace.com/drug-development/biogen-eisais-leqembi-gets-uk-approval-but-deemed-too-expensive-by-nice
3. https://nice.org.uk/news/articles/benefits-of-new-alzheimer-s-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs
4. https://reuters.com/business/healthcare-pharmaceuticals/drugmaker-biogen-forecasts-2025-profit-below-expectations-2025-02-12/
5. https://investors.biogen.com/node/28856/html
6. https://macrotrends.net/stocks/charts/BIIB/biogen/pe-ratio
7. https://reuters.com/business/healthcare-pharmaceuticals/eu-drugs-regulator-recommends-alzheimers-drug-eisai-biogen-2024-11-14/
8. https://reuters.com/business/healthcare-pharmaceuticals/lillys-alzheimers-drug-approved-uk-2024-10-23/
9. https://reuters.com/business/healthcare-pharmaceuticals/biogen-ceo-sees-no-burning-need-more-acquisitions-2025-01-14/
10. https://reuters.com/business/healthcare-pharmaceuticals/biogen-expects-steady-growth-alzheimers-drug-leqembi-near-term-2024-12-03/
11. https://reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/
12. https://reuters.com/business/healthcare-pharmaceuticals/eu-medicines-regulator-rejects-eli-lillys-alzheimers-drug-2025-03-28/

For informational purposes only; not investment advice.